Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 13, 18, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ocular Hypertension - Overview
Ocular Hypertension - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ocular Hypertension - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ocular Hypertension - Companies Involved in Therapeutics Development
Ocular Hypertension - Drug Profiles
Ocular Hypertension - Dormant Projects
Ocular Hypertension - Discontinued Products
Ocular Hypertension - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: Nicox’s NCX 470 Dolomites phase 2 results published in Journal of Glaucoma
Feb 21, 2022: Nicox granted new patent for NCX 470 in China, extending coverage to 2039
Feb 11, 2022: Ocular therapeutix announces upcoming presentation of OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
Dec 16, 2021: Nicox announces first patient in China screened in the ongoing NCX 470 Denali phase 3 trial in glaucoma
Nov 25, 2021: Notice of application for domestic manufacturing and marketing approval for K-232 treatment for glaucoma and ocular hypertension (ripasudil hydrochloride hydrate and brimonidine tartrate fixed combination eye drop)
Nov 10, 2021: Nicox’s NCX 470 Dolomites phase 2 results in glaucoma patients to be presented at the AAO 2021 Annual Meeting
Oct 13, 2021: Aerie reports positive Phase III data for netarsudil ophthalmic solution
Sep 29, 2021: Nicox’s NCX 470 shows retinal cell protection in a nonclinical model
Sep 02, 2021: Zhaoke Ophthalmology: Pivotal phase 3 clinical trial of Levobetaxolol hydrochloride eye drops met its primary endpoint
Jun 23, 2021: Nicox’s NCX 470 dolomites phase 2 results in glaucoma patients to be presented at the World Glaucoma E-Congress 2021
Jun 21, 2021: Aerie Pharmaceuticals to present update on Rhopressa at the Raymond James Human Health Innovation Conference
May 14, 2021: SPARC announces positive top-line results from pivotal phase 3 clinical trial of PDP-716 for the treatment of open angle glaucoma or ocular hypertension
Mar 16, 2021: MediPrint Ophthalmics announces successful completion of its SIGHT-1 phase 2a clinical study
Jan 20, 2021: Ocular Therapeutix presents interim topline data from the phase 1 clinical trial of OTX-TIC in patients with primary open angle glaucoma or ocular hypertension at the 10th Annual Glaucoma 360 New Horizons Forum
Dec 11, 2020: Aerpio announces statistically significant topline results from Razuprotafib glaucoma phase 2 trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Ocular Hypertension, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ocular Hypertension - Pipeline by Aadi Bioscience Inc, 2022
Ocular Hypertension - Pipeline by AbbVie Inc, 2022
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, 2022
Ocular Hypertension - Pipeline by Angelini Spa, 2022
Ocular Hypertension - Pipeline by Betaliq Inc, 2022
Ocular Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, 2022
Ocular Hypertension - Pipeline by Future Medicine Co Ltd, 2022
Ocular Hypertension - Pipeline by Glaukos Corp, 2022
Ocular Hypertension - Pipeline by Graybug Vision Inc, 2022
Ocular Hypertension - Pipeline by Ikarovec Ltd, 2022
Ocular Hypertension - Pipeline by Jenivision Inc, 2022
Ocular Hypertension - Pipeline by Kowa Co Ltd, 2022
Ocular Hypertension - Pipeline by Laboratoires Thea SA, 2022
Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, 2022
Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022
Ocular Hypertension - Pipeline by MediPrint Ophthalmics Inc, 2022
Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, 2022
Ocular Hypertension - Pipeline by NicOx SA, 2022
Ocular Hypertension - Pipeline by Noveome Biotherapeutics Inc, 2022
Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, 2022
Ocular Hypertension - Pipeline by pH Pharma Co Ltd, 2022
Ocular Hypertension - Pipeline by Qlaris Bio Inc, 2022
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, 2022
Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, 2022
Ocular Hypertension - Pipeline by Shenzhen Hornetcorn Bio-technology Company Ltd, 2022
Ocular Hypertension - Pipeline by Skye Bioscience Inc, 2022
Ocular Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
Ocular Hypertension - Pipeline by Sun Pharmaceutical Industries Ltd, 2022
Ocular Hypertension - Pipeline by Sustained Nano Systems LLC, 2022
Ocular Hypertension - Pipeline by Sylentis SAU, 2022
Ocular Hypertension - Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
Ocular Hypertension - Pipeline by ViSci Ltd, 2022
Ocular Hypertension - Pipeline by Visus Therapeutics Inc, 2022
Ocular Hypertension - Pipeline by Whitecap Biosciences LLC, 2022
Ocular Hypertension - Dormant Projects, 2022
Ocular Hypertension - Dormant Projects, 2022 (Contd..1)
Ocular Hypertension - Discontinued Products, 2022
List of Figures
Number of Products under Development for Ocular Hypertension, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
